Publications by authors named "A Koenen"
Background: Angiosarcoma is a rare and aggressive cancer of the endothelial cells. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been described in several case reports. The aim of this trial was to prospectively evaluate the anti-tumor activity of propranolol monotherapy in patients with angiosarcoma before proceeding to standard of care treatment.
View Article and Find Full Text PDFNeoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients.
Ann Surg Oncol
December 2023
Article Synopsis
- Neoadjuvant imatinib is an effective treatment for large or locally advanced gastrointestinal stromal tumors (GISTs), as it helps decrease tumor size, leading to more successful surgeries and higher rates of complete tumor removal (R0 resection).
- A study of 113 patients showed that a high percentage (95%) underwent surgery after treatment, with significant tumor size reduction in 88% of cases, particularly in those with specific genetic mutations (KIT exon 11).
- The majority of patients (51%) had their surgical strategy adjusted, with a low complication rate (15%) and promising long-term survival rates (80% disease-free and 91% overall after five years).
Background: Cryptococcus gattii is a globally endemic pathogen causing disease in apparently immune-competent hosts. We describe a 22-year cohort study from Australia's Northern Territory to evaluate trends in epidemiology and management, and outcome predictors.
Methods: A retrospective cohort study of all C.
Purpose: A prior phase I study showed that the neo-adjuvant combination of pazopanib and radiotherapy was well tolerated, and induced promising pathological responses in soft-tissue sarcoma patients. Results of the subsequent prospective, multicenter phase II, PASART-2 trial are presented here, further investigating the efficacy and safety of this combination.
Patients And Methods: Patients with high-risk, localized soft-tissue sarcoma received neo-adjuvant radiotherapy, 50 Gy in 25 fractions (PASART-2A) or with a subsequent dose de-escalation to 36 Gy in 18 fractions (PASART-2B).
Background Statins inhibit the cholesterol biosynthesis and are used as cholesterol-lowering agents in fat-metabolism disorders. Furthermore, several studies state that statins have supportive functions in breast cancer treatment. Therefore, simvastatin (SVA) as a potential radiosensitizer should be investigated on the basis of human breast cells.
View Article and Find Full Text PDF